Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22616905 | 0.76 | THRB (0.32) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL17008829 | 0.76 | KDM4E (0.34) | — | |
| Hydrochloric Acid SCHEMBL28662106 | 0.74 | MEN1 (0.32) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL16242531 | 0.71 | THRB (0.34) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL28666658 | 0.68 | THRB (0.32) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL7907689 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL28662631 | 0.67 | THRB (0.31) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL28675804 | 0.67 | THRB (0.31) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL22616620 | 0.64 | — | — | |
| SCHEMBL28676393 | 0.64 | SIGMAR1 (0.36) | MEN1LMNAMAPTTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441748-B2 | Metal-ligand complexes | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-10-14 | — | — | US | disclosed |
| CN-113748140-B | Metal-ligand complexes | 陶氏环球技术有限责任公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20220259231-A1 | METAL-LIGAND COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962970-A1 | METAL-LIGAND COMPLEXES | Dow Global Technologies LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-113748140-A | Metal-ligand complexes | 陶氏环球技术有限责任公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2020223142-A1 | METAL-LIGAND COMPLEXES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259231-A1 | METAL-LIGAND COMPLEXES | ARL1, CRKL, SAAL1 | MEN1 1113/4885LMNA 2908/4885MAPT 4710/4885 |
| US-12441748-B2 | Metal-ligand complexes | ARL1, CRKL, SAAL1 | MEN1 1113/4885LMNA 2908/4885MAPT 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.